Abstract
Special populations need to be investigated to enable valid prescribing information in these patients to be given to the medical practitioner. The risk/benefit ratio was generally considered not to be uniform for all sectors of the population. Efficacy was not generally regarded as being in debate, but it was considered that the toxicological pro-file could vary with sectors of the population.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wardell, W.M., Velo, G. (1981). Special Populations: Summary of the Discussion. In: Wardell, W.M., Velo, G. (eds) Drug Development, Regulatory Assessment, and Postmarketing Surveillance. NATO Advanced Study Institutes Series, vol 39. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4055-3_10
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4055-3_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4057-7
Online ISBN: 978-1-4684-4055-3
eBook Packages: Springer Book Archive